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Abstract This report is a retrospective analysis of 65 patients
with peripheral T cell lymphoma (PTCL), who underwent
high-dose therapy and autologous hematopoietic stem cell
transplantation (autoHCT) as a consolidation of first response
achieved with either induction or salvage chemotherapy. We
intended to determine the prognostic factors that influenced
outcome after autoHCT and to define the predictive value of
the scoring systems most often applied for transplant out-
comes. Nineteen patients in either complete or partial
remission underwent autoHCT after induction chemotherapy.
Forty-six patients received second-line chemotherapy as a
consolidation of partial response after induction chemothera-
py (n=34) or as a salvage therapy after primary induction
failure (n=12), and thereafter proceeded to autoHCT. Finally,
the 36 patients were in complete remission, and 29 in partial
remission at autoHCT. The median follow-up of survivors
was 53 months (range 7–157 months). The 5-year overall
survival and progression-free survival for all patients were
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61.5 % (95 % CI 47.0–74.2 %) and 59.4 % (95 % CI 46.1–
71.5 %), respectively. In multivariate analysis, bone marrow
involvement at diagnosis and less than partial remission after
induction chemotherapy were factors independently predic-
tive for overall survival and progression-free survival. The
prognostic index for PTCL could reliably stratify the progno-
sis of PTCL in this analysis.
Keywords Peripheral Tcell lymphoma . Autologous
hematopoietic stem cell transplantation . Prognostic factors .
Clinical outcomes . Scoring systems
Introduction
Although peripheral T cell lymphomas (PTCL) are relative-
ly uncommon disorders, representing only 8–15 % of all
non-Hodgkin lymphomas, some estimates have been
reported indicating that the incidence of PTCL has been
increasing for the last two decades, faster that the incidence
of B cell lymphomas [1, 2]. The nodal types of PTCL,
which include peripheral T cell lymphoma not otherwise
specified (PTCL-NOS), anaplastic large cell lymphomas
(ALCLs), and angioimmunoblastic T cell lymphoma, are a
heterogenous group of diseases that are challenging to treat.
Most PTCL subtypes have a poor prognosis with a 5-year
survival rate of approximately 30 % and a median survival
of 2–3 years [3, 4]. The exception is patients with anaplastic
lymphoma kinase (ALK)-positive ALCL, who have a 5-
year survival rate of about 60–90 % with conventional
chemotherapy [3, 5]. Although the outcome of patients with
PTCL is worse than that of patients with aggressive B cell
lymphomas [6, 7], they are treated similarly with the CHOP
or CHOP-like regimens used as an induction chemotherapy.
Unfortunately, even up to 40 % of patients experience
primary induction failure or early relapse after CHOP-like
chemotherapy [4, 8, 9]. Moreover, the best treatment option
for patients with PTCL who have responded to the conven-
tional chemotherapy remains undefined. Several prospective
phase II trials, as well as the results of retrospective studies,
support high-dose therapy (HDT) followed by autologous
hematopoietic stem cell transplantation (autoHCT) as a con-
solidation of first response for PTCL. Although autoHCT
seems to extend progression-free survival (PFS) and overall
survival (OS), unfortunately 20–40 % of patients will re-
lapse following autotransplant [8, 10–12]. Since relapse re-
mains the primary cause of autoHCT failure, allogeneic
HCT after reduced intensity conditioning (RIC) regimen is
sometimes offered to the selected patients in first remission,
primary with high-risk histological subtypes of PTCL
[13–15]. In addition, a variety of new drugs registered in
relapsed disease are being studied in the upfront setting [16].
Hence, better characterization of prognostic factors, as well
as validation of prognostic scores used in the transplant
setting, is required for improved patient selection for
autoHCT. The scoring systems most often applied in the
literature of HCT for PTCL are the International Prognostic
Index (IPI) and the Prognostic Index for Peripheral T cell
Lymphoma not otherwise specified (PIT). The latter index is
based on age, performance status, lactate dehydrogenase
(LDH), and bone marrow involvement [17]. The usefulness
of the IPI has been questioned in some studies in the
autotransplant setting [8, 18]. In contrast, the PIT has been
reported to be more accurate in stratifying PTCL patients
undergoing autoHCT [8, 18, 19].
Since the results reported by several groups around the
world suggested that HDT and autoHCT was beneficial in
PTCL in the front-line setting, patients in first remission
have been considered for autotransplant at our centers for
more than decade now. To expand the published experience,
we conducted a multicenter, retrospective review of patients
with PTCL who underwent HDT and autoHCT as a consol-
idation of first response achieved with either initial induc-
tion chemotherapy or salvage chemotherapy. We intended to
determine the overall survival, the progression-free survival,
and the prognostic factors that influenced outcome after
autoHCT. We also intended to define the predictive value
of IPI and PIT scores for transplant outcomes of patients
with PTCL in first remission. Herein, we report the results
of this analysis.
Patient selection
The records of all patients with a confirmed diagnosis of
peripheral T cell lymphoma receiving HDT and autoHCT
between 1998 and 2011 at each of the seven centers partic-
ipating in the present retrospective analysis were reviewed.
Included in the study were patients who received autoHCT
in first response achieved with either induction or salvage
chemotherapy. All the patients with primary cutaneous lym-
phoma were excluded from the analysis. The patients with
ALK-positive ALCL and ALK-unknown ALCL who re-
ceived autoHCT as a consolidation of first complete re-
sponse achieved with the initial induction chemotherapy
were also excluded from the study. In contrast, patients with
ALK-positive and ALK-unknown ALCL who had achieved
less than complete response after induction chemotherapy
and received afterwards HDT and autoHCT, either preceded
or not by second-line chemotherapy, were included in the
analysis.
Data collection and definitions
Patients records were reviewed to obtain baseline character-
istic at the time of diagnosis (clinical stage, presence of B
symptoms, performance status, bone marrow involvement,
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involvement of extranodal sites, mediastinal lymph node
involvement, LDH, IPI score, PIT score). Complete re-
sponse (CR), partial response (PR), and disease progression
were defined using standard criteria [20]. Primary induction
failure (PIF) was defined as the achievement less than partial
response after induction chemotherapy.
Statistical analysis
The endpoints were overall and progression-free survival.
Survival curves were estimated according to the method of
Kaplan and Meier. OS was measured from the time of
transplantation until death from any cause and PFS was
measured from the time of transplantation until documented
progression or relapse or death from any reason.
The two-tailed logrank test was utilized to compare the
curves. p values <0.05 were considered significant. Potential
prognostic factors, histology, clinical stage, presence of B
symptoms, bone marrow involvement, extranodal sites, me-
diastinal involvement, LDH, performance status, response
to initial induction chemotherapy, a total number of chemo-
therapy lines before autoHCT, and disease status at trans-
plant were evaluated for OS and PFS in univariate analysis.
Cox proportional hazards model was used for multivariable
analysis.
The predictive value of the IPI and PIT scoring systems for
transplant outcome survival probabilities were estimated using
Kaplan and Meier method. The logrank test was used to
compare survival curves. HRs and 95 % confidential intervals
(95 % CI) were determined using Cox regression method.
SPSS version 14.0 (SPSS, Chicago, IL) was used for all
statistical analyses.
Results
Patient characteristics, prior treatment, and transplantation
procedures details
From January 1998 to December 2011, the 65 patients
(32 men and 33 women) received HDT and autoHCT as
a consolidation of first response achieved with either
induction or salvage chemotherapy. The median age at
transplant was 42 years (range 15–64 years). Patient
baseline characteristics are presented in Table 1. Fifty
nine of the 65 patients (91 %) had received CHOP or
CHOP-like regimen as an induction chemotherapy.
Twelve patients in complete response and seven patients
in partial response proceeded to autoHCT after induction
chemotherapy. Thirty-four of the 65 patients (52 %) re-
ceived second-line chemotherapy as a consolidation of
partial response achieved with the induction chemother-
apy and thereafter proceeded to autoHCT. The decision
about consolidation of partial response with second-line
chemotherapy was taken by the responsible physician. The
decision depended on the tumor burden after induction che-
motherapy and the practice of institutions involved in the
study. Patients in partial response were considered to receive
second-line chemotherapy at five of the seven institutions
participating in this study. Twelve of the 65 patients (18 %)
received second-line chemotherapy as a salvage treatment after
primary induction failure. Having achieved at least a partial
remission after salvage treatment, they underwent autoHCT.
The patients received a median of two (range 1–4) chemother-
apy lines. Finally, 36 patients were in CR and 29 in PR at
autoHCT, respectively. The autologous graft source was mo-
bilized peripheral blood in 95 % of all cases. The median
number of infused CD34 positive cells was 5.6×106 cells/kg
(range, 1.6–22.8). Institutional transplant guidelines for sup-
portive care were followed. Antiemetics prophylaxis was
based on ondansetron. Antifungal, antiviral, and antibacterial
prophylaxis included fluconazole, acyclovir, and ciprofloxacin
or norfloxacin until neutrophil recovery. Packed red blood cells
were administered to maintain Hb levels ≥4.8 mmol/L. Platelet
transfusions were administered to keep platelet count ≥10 or ≥
20 G/L in patients with increased risk of bleeding complica-
tions. Engraftment was documented in all but one patient who
died within 10 days of transplant from infection. Recovery to
granulocyte count >0.5 G/l occurred at a median 13 days
(range, 10–18 days). Table 2 shows chemotherapy and trans-
plant details.
Posttransplantation outcomes
All patients were evaluated for survival, with a median
follow-up time of surviving patients of 53 months (range
7–157 months). A detailed analysis was carried out at the
censor date (30 April 2012). Twenty-one (32 %) patients in
our study have died. The cause of death in 17 patients was
progressive disease. Four patients have died from non-
relapse causes, corresponding to non-relapse mortality of
6 %. Two of the four patients have died as a result of
infections, one patient died from heart failure 12 years after
autoHCT, and one patient died 55 months after transplant as
a consequence of a post-transplant diagnosed glioblastoma.
With regard to secondary hematologic malignancies, one
acute myeloid leukemia was observed 4 years after
autoHCT that was successfully treated with chemotherapy
at the time of the censor date.
At 3 and 5 years after transplantation, estimated OS for all
patients was 74.7 % (95 % CI 62.2–84.1 %) and 61.5 % (95%
CI 47.0–74.2 %), respectively (Fig. 1). The respective PFS
rates were 62.2% (95%CI 49.5–73.4%) and 59.4% (95%CI
46.1–71.5 %) (Fig. 1). When patients were stratified by the
response to the induction chemotherapy, the 5-year OS esti-
mates were 66.0 % (95 % CI 49.9–79.1 %) and 41.0 % (95 %
Ann Hematol (2013) 92:925–933 927
CI 16.6–70.9 %) for patients with PR/CR after first-line che-
motherapy and with primary induction failure, respectively
(p=0.05). The corresponding 5-year PFS rates were 65.2 %
(95 % CI 50.0–77.8 %) and 33.3 % (95 % CI 6.6–60.0 %)
(p=0.004).
Univariate analysis identified several risk factors for
OS and PFS (Table 3). Two factors were found to be
significant for OS: bone marrow involvement at diagno-
sis (p=0.004) and response to induction chemotherapy
(p=0.050). Clinical stage at diagnosis and the presence
of B symptoms tended to impact OS (p=0.099 and
0.066, respectively). Poor PFS was associated with the
presence of B symptoms at diagnosis (p=0.023), bone
marrow involvement at diagnosis (p=0.002), and prima-
ry induction failure (p=0.004). In multivariate analysis,
bone marrow involvement at diagnosis and primary
induction failure remained significant for both OS and
PFS (Table 4).
In contrast, histology type (ALK-positive and ALK-
unknown ALCL vs other types), LDH at diagnosis,
extranodal involvement, mediastinal lymph nodes involve-
ment, the number of pre-transplant chemotherapy lines, and
the disease status at transplant (CR vs PR) were predictive
for neither OS nor PFS (Table 3).
Table 1 Baseline patient and disease characteristics
Characteristics at diagnosis Number (%)
Total number of pts 65 (100)
Age (years), median 42, range 15–64
≤60 years 61 (94)
>60 years 4 (6)
Gender
Male 32 (49)
Female 33 (51)
Histology
PTCL not otherwise specified 36 (55)
AITL 9 (14)
ALCL 20 (31)
ALK-negative 7 (11)
ALK-positive 4 (6)
ALK-unknown 9 (14)
Ann Arbor stage
I–II 14 (21.5)
III–IV 50 (77)
Unknown 1 (1.5)
Constitutional symptoms
Absent 14 (21.5)
Present 51 (78.5)
BM involvement
No 44 (68)
Yes 16 (24.5)
Unknown 5 (7.5)
IPI score
0–1 16 (25)
2 17 (26)
3–4 24 (37)
Unknown 8 (12)
PIT score
0 10 (15)
1 23 (35)
2–3 18 (28)
Unknown 14 (22)
PTCL peripheral T cell lymphoma, IPI International Prognostic Index,
PIT Prognostic Index for peripheral T cell lymphoma, AITL
angioimmunoblastic T cell lymphoma, ALCL anaplastic large cell
lymphoma, ALK anaplastic lymphoma kinase
Table 2 Previous treatment and transplant details
Treatment details Number (%)
Induction chemotherapy
CHOP 57 (88)
CHOP and etoposide 2 (3)
Others anthracycline-containing combination
chemotherapies
6 (9)
Response after induction chemotherapy
CR 12 (18)
PR 41 (64)
Primary refractorinessa 12 (18)
Second-line chemotherapy 46 (71)
ESHAP or DHAP 27 (42)
Other platinum-containing regimen 4 (6)
Others 15 (23)
Number of pre-transplant regimens
1 18 (28)
2 42 (65)
>2 5 (7)
Disease status at autoHSCT
CR 36 (55)
PR 29 (45)
Autologous graft source
Mobilized peripheral blood 62 (95)
Bone marrow 3 (5)
The number of infused CD34 positive cells ×106/kg
Median 5.6
Range 1.6–22.8
Conditioning regimen
BEAM 38 (58)
CBV 18 (28)
CyTBI 3 (5)
Others 6 (9)
CR complete response, PR partial response
a Less than PR
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Fig. 1 Kaplan–Meier estimates
of overall survival (OS) and
progression-free survival (PFS)
for the whole group
Table 3 Univariate analysis of prognostic factors associated with overall survival and progression-free survival
Group No. 5-year OS (95 % CI) p value 5-year PFS (95 %) p value
Ann Arbor stage
I–II 14 84.6 (57.8–95.7) 0.099 78.6 (52.3–92.5) 0.10
III–IV 50 53.0 (36.5–68.8) 52.1 (36.8–67.0)
B symptoms at diagnosis
No 14 83.3 (55.1–95.3) 0.066 85.1 (58.8–95.8) 0.023
Yes 51 53.8 (37.3–69.5) 51.5 (36.6–66.2)
Bone marrow involvement at diagnosis
No 44 69.2 (50.9–82.9) 0.004 69.9 (53.7–82.3) 0.002
Yes 16 34.9 (15.1–61.9) 24.1 (8.8–51.1)
Response to induction regimen
≥PR 53 66.0 (49.9–79.1) 0.050 65.2 (50.0–77.8) 0.004
Primary refractorinessa 12 41.0 (16.6–70.9) 33.3 (6.6–60.0)
Disease status at transplant
CR 36 65.7 (46.9–80.6) 0.46 64.5 (46.3–79.3) 0.23
less than CR 29 57.1 (35.5–76.3) 54.7 (36.5–72.9)
Number of prior chemotherapy regimen
1 19 77.2 (53.7–90.7) 0.17 78.7 (56.6–90.8) 0.08
2 or more 46 56.8 (40.7–71.6) 51.7 (36.9–66.2)
Histology
ALK-positive and ALK-unknown ALCL 13 54.2 (26.2–79.8) 0.70 59.8 (33.4–81.5) 0.89
Other types 52 63.3 (47.1–77.0) 59.3 (44.4–72.6)
ALCL-all subtypes 20 63.6 (38.8–82.8) 0.77 63.8 (41.7–81.3) 0.70
PTCL-NOS and AITL 45 60.7 (43.4–75.7) 57.5 (41.5–72.1)
ALK-positive and ALK-unknown ALCL 13 54.2 (26.2–79.8) 0.74 59.8 (33.4–81.5) 0.62
ALK-negative ALCL 7 83.3 (43.7–97.0) 71.4 (35.8–91.8)
PTCL-NOS 36 60.7 (42.3–76.5) 55.8 (39.0–71.3)
AITL 9 55.6 (18.0–87.7) 55.6 (18.0–87.7)
OS overall survival, PFS progression-free survival, CI confidence interval, CR complete response, PR partial response, ALK anaplastic lymphoma
kinase, ALCL anaplastic large cell lymphoma, PTCL peripheral T cell lymphoma, NOS not otherwise specified, AITL angioimmunoblastic T cell
lymphoma
a Less than PR
Ann Hematol (2013) 92:925–933 929
Performance of risk models in prediction of outcome
after autoHCT
Table 5 shows PIT and IPI performance in prediction of
OS and PFS. Regarding PIT, only few studied patients
were considered high-risk (score ≥3), so this small group
was combined with intermediate–high-risk group (score
2). The 5-year OS was 89, 57, and 32 % for low (score
0), low–intermediate (score 1), and combined intermedi-
ate–high-risk and high-risk groups, respectively
(p=0.024, logrank test) (Fig. 2a). PIT score could reli-
ably delineate score ≥2 risk group (HR 9.27; p=0.033).
However, PIT did not show statistical significant dis-
crimination between patients with low- and low–interme-
diate-risk (HR 3.73; p, 0.22). Consequently, patients
were divided into two groups according to a simplified
two-class PIT. A simplified PIT provided a good dis-
crimination between score 0–1 and score ≥2 risk group
(HR 3.45; p, 0.011). In contrast to PIT, neither IPI nor a
simplified two-class IPI was able to predict outcome
after autoHCT (Fig. 2b).
Having found bone marrow involvement and primary
induction failure as the only independent predictors of OS
and PFS in the multivariate analysis, we classified the pa-
tients according to the number of identified independent
unfavorable factors for outcome. The 2-year OS estimates
were 72.1, 47.5, and 25 % for patients with zero, one, and
two risk factors, respectively (p<0.001) (Fig. 2c). The me-
dian overall survival was not reached for patients with none
of the risk factors, compared to 57 months for patients with
one risk factor and 4 months for patients with two risk
factors. The respective 2-year PFS estimates were 73.4,
39.0, and 0 % (p<0.001).
Discussion
There are limited published prospective data regarding the
outcomes of autologous stem cell transplantation in patients
with peripheral T cell lymphoma. In addition, more exten-
sive retrospective data are difficult to interpret. Most of the
reported retrospective studies have been small and have
included both patients with relapsed disease and those in
first remission, as it has been pointed out in published
reviews of the literature [21–23]. To overcome those limi-
tations, we have included in the present analysis patients in
first complete or partial remission after induction chemo-
therapy and patients with primary induction failure, who
achieved at least partial remission after salvage treatment.
Moreover, we have excluded patients with ALK-positive
and ALK-unknown ALCL who were transplanted in first
complete remission achieved with an initial induction
Table 4 Summary of results
from overall survival and pro-
gression-free survival Cox
model
HR hazards ratio, CI confidence
interval, CR complete response,
PR partial response
aLess than PR
Group Overall survival Progression-free survival
HR (95 % CI) p value HR (95 % CI) p value
Response to induction chemotherapy
Primary refractorinessa vs ≥PR 3.21 (1.17–8.79) 0.023 4.56 (1.86–11.19) 0.001
Marrow involvement at diagnosis
Yes vs no 3.85 (1.51–9.78) 0.005 3.58 (1.55–8.27) 0.003
Table 5 Performance of different scoring models in prediction of survival
Risk model Risk group
stratification
5-year OS
(95 % CI)
HR (95 % CI) p
value
5-year PFS
(95 % CI)
HR (95 % CI) p
value
IPI Low (score 0–1) 77.9 (51.2–92.2) 1 0.12 74.5 (49.8–89.6) 1 0.23
Int-1 (score 2) 27.3 (8.3–60.8) 3.90 (1.03–14.8) 0.046 28.5 (9.3–60.7) 2.76 (0.85–9.03) 0.09
Int-2 and high
(score 3–5)
53.1 (30.9–74.1) 2.16 (0.58–8.0) 0.25 51.1 (31.3–70.6) 2.29 (0.72–6.94) 0.17
PIT Low (score 0) 88.9 (56.4–98.0) 1 0.036 90.0 (59.5–98.2) 1 0.059
Low–int (score 1) 57.4 (30.4–80.6) 3.73 (0.45–31.13) 0.22 51.8 (28.6–74.3) 5.21 (0.66–41.31) 0.118
Int and high (score 2–3) 31.8 (7.7–55.9) 9.27 (1.19–72.11) 0.033 32.4 (15.3–55.9) 9.52 (1.23–73.51) 0.031
Simplified
two-class PIT
Score 0–1 70.0 (50.0–90.0) 1 65.4 (47.0–83.8) 1
Score 2–3 31.8 (7.7–55.9) 3.45 (1.33–8.91) 0.011 32.4 (15.3–55.9) 2.59 (1.12–6.01) 0.027
OS overall survival, HR hazards ratio, IPI the International Prognostic Index, PIT the Prognostic Index for peripheral T cell lymphoma, Int
intermediate
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Fig. 2 Kaplan–Meier estimates
of overall survival (OS) a
stratified by PIT score; b
stratified by IPI score; and c
stratified by the following risk
factors: bone marrow (BM)
involvement at diagnosis,
primary induction failure (PIF)
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chemotherapy to make the results more clear for interpreta-
tion, as ALK-positive ALCL is known to carry a better
outcome comparing to other histological subtypes of
PTCL. Among the 65 patients in this report, 36 of them
underwent autoHCT in complete remission, whereas 29
patients were in partial remission at transplant. The 5-year
OS for all patients was 61.5 %, what is consistent with
previous reports of prospective and retrospective studies,
across which the range of OS was from 48 to 68 % at 4–
5 years for patients transplanted in first remission [10, 11,
18, 24, 25]. We did not find a statistically significant sur-
vival difference by histological subtype of PTCL. Similarly
to our results, some previous studies also showed no differ-
ence in survival after autoHCT based on histology [11, 25]. In
addition, our study did not show that disease status at trans-
plant (CR vs PR) significantly affected survival after autoHCT.
However, it should be pointed out that the difference in sur-
vival based on disease status at transplant was found mostly in
the studies including patients with both chemosensitive and
chemorefractory disease at transplant [11, 19, 25]. Moreover,
those studies included both patients in first remission and
patients in second remission achieved after previous relapse.
In contrast to disease status at transplant, we identified B
symptoms at diagnosis, bone marrow involvement at diagno-
sis, and refractoriness to induction chemotherapy as risk fac-
tors adversely influencing overall survival and progression-
free survival after autoHCT in univariate model. In multivari-
ate analysis, bone marrow involvement at diagnosis and re-
sponse to induction chemotherapy remained the only
independent prognostic factors associated with OS and PFS.
Our results based on limited number of patients suggest that
the transplant outcomes for patients with bone marrow in-
volvement at diagnosis and primary refractoriness to induction
chemotherapy are very poor with 25 % alive at 5 years, in
contrast to 47 and 72 % survivors among patients with one risk
factor and without any of those independent risk factors,
respectively. Although the group of patients with two risk
factors was very small, consisting of only four patients, it is
worth pointing out that all of those patients experienced disease
progression within 8 months of autoHCT, and three of them
died from that reason.
We also evaluated the predictive value of the IPI and PIT
scoring systems for transplant outcome in patients with
PTCL. The prospective trials have shown conflicting results
regarding the role of the IPI index. The IPI score did not
provide a good discrimination between the risk groups prior
to autoHCT in the current analysis, which is in line with the
results of the both German and Spanish prospective multi-
center trials [8, 18], but in contrast to the results of the
Italian prospective study [26]. The PIT score initially pro-
posed by Gallamini and coworkers for patients with PTCL-
NOS was previously reported to be predictive for transplant
outcome [8, 18, 19]. Although this model reliably delineated
the combined intermediate–high- and high-risk group in the
current analysis, it failed to discriminate well between low-
and low–intermediate-risk categories. However, a simplified
PIT provided a good discrimination between score 0–1 and
score ≥2 risk group (p=0.011), with 70 % of patients alive at
5 years in low-risk group, in contrast to 32 % in high-risk
group.
In conclusion, the treatment strategy for the patients with
bone marrow involvement at diagnosis, who did not respond
to induction chemotherapy, as well as for patients with PIT
score ≥2 at diagnosis remains an area for further studies with
newer treatment options, including RIC allogeneic HCT,
since the results of HDT followed by autoHCT are poor in
this setting. Despite the limitation of the retrospective study,
like no intent-to-treat analysis, our results support the use-
fulness of the PIT in stratifying PTCL patients undergoing
autoHCT in first remission and expanding the published
experience may be useful in patient selection for
autotransplant.
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